The VIVUS, Inc. (NASDAQ:VVUS) on Mar. 25 announced that a review article has been published online in the Journal of Hypertension, the official publication of the International Society of Hypertension and the European Society of Hypertension, summarizing the cardiovascular benefit-risk profile of Qsymia capsules CIV. The data suggest that Qsymia can be a safe and effective weight loss option for overweight/obese patients with cardiovascular risk factors such as hypertension or type 2 diabetes. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.94 moved to $5.96 on last trade day and at the end of the day closed at $5.72. Company price to sales ratio in past twelve months was calculated as 7.29 and price to cash ratio as 1.72. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -2.05%.
The Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Feb. 27 provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Fourth quarter Net loss allocable to common stockholders was $23.5 million, or $0.11 per share.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell -3.17% in last trading session and ended the day on $6.10. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -28.49%.
Investment analysts at HC Wainwright initiated coverage on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a note issued to investors on Tuesday, StockRatingsNetwork reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 84.21% from the company’s current price. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 5.00% in last trading session and was closed at $7.98, while trading in range of $7.87-$8.20. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date performance is 17.01%.
Shares of MannKind Corporation (NASDAQ:MNKD) closed down 7.12% on about 26 million shares traded this past Friday. The stock was one of the biggest losers on the NASDAQ. The drop came after a report from an FDA staff raised some questions about the company’s diabetes device Afrezza. The FDA committee said it was concerned about certain pharmacology issues that could impact Afrezza’s safety and effectiveness.MannKind Corporation (NASDAQ:MNKD) weekly performance is -17.72%. On last trading day company shares ended up $4.83. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average is -15.44%. Analysts mean target price for the company is $7.07.
Leave a Reply